TransCode Therapeutics (RNAZ)
Develops RNA-delivery and immuno-oncology candidates for metastatic and other cancers.
Something off on this page? Send us feedback.
Develops RNA-based and immuno-oncology candidates, led by a program designed to deliver an antisense therapy to metastatic tumors. It has no approved products or sales and relies on external financing, collaborators, and outsourced manufacturing to advance its portfolio.
Develops RNA-based oncology candidates designed to deliver therapeutics systemically to metastatic tumors, centered on TTX-MC138, an antisense RNA candidate in its clinical portfolio. The portfolio also includes seviprotimut-L, an investigational melanoma vaccine, additional TTX RNA programs, and licensed preclinical oncolytic-immunotherapy candidates.
Operates as a single clinical-stage business with no approved products or commercial revenue, using external capital to fund development. A small U.S. workforce works with U.S. clinical collaborators, while manufacturing is outsourced to European contract manufacturers. Progress depends on clinical-trial execution and regulatory review, manufacturing scale-up, licensed intellectual-property rights, continued financing, and Nasdaq listing compliance.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.4M · Total debt $652.4K · Total assets $151.0M · Shareholders' equity $138.4M
- Revenue
- $0
- Operating income
- −$6.8M
- Net income
- −$6.7M
No dividends on record.
| Institutions7 holders · as of Mar 31, 2026 | 0.18% | 30.9K shares | |
| Otherremainder | 99.82% | 16.90M shares |
16.93M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (16.93M in the company's Sep 3, 2026 report, 1.06M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Geode Capital Management, LLCInstitution | 0.08% | 12,740 | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.05% | 8,295 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 0.04% | 6,545 | 13Fas of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.02% | 2,982 | 13Fas of Mar 31, 2026 |
Tower Research Capital LLC (TRC)Institution | 0.00% | 228 | 13Fas of Mar 31, 2026 |
| See all 23 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
No open-market trades in the last 12 months.
- Merck
Approved adjuvant melanoma therapy and personalized mRNA-vaccine threat.
- Bristol-Myers Squibb
Approved adjuvant melanoma and urothelial-cancer checkpoint therapy.
- Moderna
Late-stage personalized mRNA vaccine for resected high-risk melanoma.
- BioNTech (ADR)
Clinical mRNA immunotherapy for advanced melanoma.
- AstraZeneca (ADR)
Approved perioperative PD-L1 therapy for muscle-invasive bladder cancer.
- Arrowhead Pharmaceuticals
RNAi platform peer with a clinical renal-cancer program.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| TransCode Therapeutics | $2.01 | −2.43% | $2.1M | — | — | — | — |
| Merck | $151.14 | −0.33% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Bristol-Myers Squibb | $67.38 | −0.40% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Moderna | $147.30 | −2.34% | $59.84B | — | — | 26.9 | +2.1% |
| BioNTech (ADR) | $104.00 | +0.22% | $26.08B | — | — | 8.5 | −60.7% |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Arrowhead Pharmaceuticals | $85.13 | −0.30% | $12.02B | — | — | 18.0 | +171.0% |
| Median | 24.3 | 15.2 | 7.1 | +5.4% |